Related Experiment Video
Updated: Mar 8, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells
1Department of Gynecology and Obstetrics, Linyi Central Hospital, Linyi, Shandong, China.
Abstract:
The objective of this study was to investigate the effect of downregulating long non-coding RNAs (lncRNAs) on the reversal of cisplatin resistance in CP70 ovarian cancer cells, and to identify the underlying mechanism(s) of action. An lncRNA microarray was performed to screen for downregulated lncRNAs in cisplatin-resistant CP70 cells. Expression levels of these lncRNAs were then verified in SKOV3 and SKOV3/DDP cells. Quantitative polymerase chain reaction was conducted to identify the lncRNA most downregulated, which was then synthesized and transfected into CP70 cells. To assess the viability and migration ability of these transfected CP70 cells, methyl thiazolyl tetrazolium and Transwell assays were carried out. In addition, expression levels of apoptosis-related proteins were examined by western blotting. The lncRNA microarray analysis and qPCR identified seven lncRNAs that were significantly downregulated. Transfection of lncRNA ENST00000457645 into CP70 cells markedly inhibited viability and migration ability, and significantly increased expression of apoptotic proteins such as Bax and cleaved caspase-3. lncRNA ENST00000457645 negatively affects the viability and migration of cisplatin-resistant CP70 ovarian cancer cells. The mechanism responsible involves modification of apoptotic protein expression.
Insights
Downregulating long non-coding RNA ENST00000457645 can reverse cisplatin resistance in ovarian cancer cells. This study identified its mechanism involving apoptosis-related protein expression, offering potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cisplatin resistance is a major challenge in ovarian cancer treatment.
- Long non-coding RNAs (lncRNAs) play crucial roles in cancer progression and drug resistance.
- Identifying novel therapeutic targets is essential for overcoming cisplatin resistance.
Purpose of the Study:
- To investigate the effect of downregulating specific lncRNAs on cisplatin resistance in CP70 ovarian cancer cells.
- To identify the lncRNA responsible for reversing cisplatin resistance.
- To elucidate the underlying molecular mechanisms, particularly involving apoptosis.
Main Methods:
- lncRNA microarray analysis to screen downregulated lncRNAs in cisplatin-resistant cells.
- Quantitative polymerase chain reaction (qPCR) to validate lncRNA expression.
- Transfection of the identified lncRNA into CP70 cells.
- Methyl thiazolyl tetrazolium (MTT) and Transwell assays to assess cell viability and migration.
- Western blotting to examine apoptosis-related protein expression.
Main Results:
- Seven significantly downregulated lncRNAs were identified.
- Transfection of lncRNA ENST00000457645 into CP70 cells inhibited cell viability and migration.
- This transfection led to increased expression of pro-apoptotic proteins, including Bax and cleaved caspase-3.
- lncRNA ENST00000457645 negatively impacts cisplatin-resistant ovarian cancer cell behavior.
Conclusions:
- lncRNA ENST00000457645 plays a role in reversing cisplatin resistance in ovarian cancer.
- Its mechanism involves the modulation of apoptosis-related protein expression.
- This lncRNA represents a potential therapeutic target for overcoming cisplatin resistance in ovarian cancer.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:56Treatment Resistant Cancers
02:15Experimental RNAi